AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2454343 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (etmozin, quinidine, mexytil, allapinin, cordarone) used alone
Number of subjects: 13
Study 2454343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of antiarrhythmic drugs
Number of subjects: 13
Study 31952554 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course therapy (SCT) - 5-day intravenous antimicrobial therapy if clinical improvement is observed
Number of subjects: 150
Study 31952554 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-course therapy (LCT) - at least 7 days of intravenous antibiotics
Number of subjects: 150
Study 31601228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical mentorship program implemented in 48 health facilities
Number of subjects: 72
Study 31601228 — intervention group
Group type: COMPARATOR
Intervention: No clinical mentorship program in 24 health facilities
Number of subjects: 72
Study 28267469 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 15750
Study 25223883 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Number of subjects: 24
Study 25223883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Number of subjects: 24
Study 23477576 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention information
Number of subjects: 1388
Study 23477576 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention motivation
Number of subjects: 1388
Study 23477576 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention behavioral skills
Number of subjects: 1388
Study 23477576 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention information and motivation
Number of subjects: 1388
Study 22147778 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen therapy
Number of subjects: 69
Study 22147778 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 69
Study 19567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocumarine 1 mg/day for 3 days before and 8 days after CVC insertion
Number of subjects: 450
Study 19567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion
Number of subjects: 450
Study 19567452 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant treatment (NT)
Number of subjects: 450
Study 19567452 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between acenocumarine and dalteparin
Number of subjects: 450
Study 19567452 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Acenocumarine, Dalteparin, NT)
Number of subjects: 450
Study 15824849 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-based phosphate binders
Number of subjects: 52
Study 15824849 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer
Number of subjects: 52
Study 10512128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CI) cisplatin 5 mg/m2/day plus etoposide 18 mg/m2/day for 5 days per week over 5 weeks with concurrent single daily fraction thoracic radiotherapy to 4500 cGy
Number of subjects: 19
Study 8929242 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 1800
Study 8929242 — intervention group
Group type: COMPARATOR
Intervention: Iron sulphate
Number of subjects: 1800
Study 8929242 — intervention group
Group type: COMPARATOR
Intervention: Iron-polysterene sulphonate
Number of subjects: 1800
Study 8929242 — intervention group
Group type: COMPARATOR
Intervention: Reference drugs
Number of subjects: 1800
Study 2202264 — intervention group
Group type: EXPERIMENTAL
Intervention: TUR + BCG (75 mg)
Number of subjects: 98
Study 2202264 — intervention group
Group type: COMPARATOR
Intervention: TUR alone (control group)
Number of subjects: 98
Study 2202264 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (75 mg) for therapy of carcinoma in situ
Number of subjects: 98
Study 6788318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 2
Study 6788318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31888744 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 88
Study 31888744 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous acupoint pseudo-electric stimulation (Sham TEAS)
Number of subjects: 88
Study 30069864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 6354
Study 30069864 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal Ranibizumab (IVR)
Number of subjects: 6354
Study 26809984 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib monotherapy (G)
Number of subjects: 236
Study 26809984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G)
Number of subjects: 236
Study 24152888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupole butterfly coil (Bfly)
Number of subjects: 15
Study 24152888 — intervention group
Group type: COMPARATOR
Intervention: MultiPurposeL coil (MPL)
Number of subjects: 15
Study 22372508 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan + amlodipine + HCTZ
Number of subjects: 180
Study 22372508 — intervention group
Group type: COMPARATOR
Intervention: olmesartan + amlodipine + HCTZ
Number of subjects: 180
Study 19012880 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing and information group (n=31)
Number of subjects: 67
Study 19012880 — intervention group
Group type: COMPARATOR
Intervention: Information control group (n=36)
Number of subjects: 67
Study 17208587 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 83
Study 17208587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15872123 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-TIVA
Number of subjects: 30
Study 15872123 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-S
Number of subjects: 30
Study 15872123 — intervention group
Group type: COMPARATOR
Intervention: Control-TIVA
Number of subjects: 30
Study 15872123 — intervention group
Group type: COMPARATOR
Intervention: Control-S
Number of subjects: 30
Study 12192468 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 191
Study 9664839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modality variations in stimulus identification and code access processes
Number of subjects: 0
Study 9664839 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance variations and end‐term variations
Number of subjects: 0
Study 9664839 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐term and distance effects
Number of subjects: 0
Study 9664839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modality and end‐term effects
Number of subjects: 0
Study 9664839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus modality variation
Number of subjects: 0
Study 7656958 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 7656958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2568971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 10
Study 2568971 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 10
Study 2568971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10
Study 2568971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 10
Study 2568971 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 10
Study 2568971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30919638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated water
Number of subjects: 30
Study 30919638 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouth-rinse
Number of subjects: 30
Study 28159027 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview (FTFI)
Number of subjects: 616
Study 28159027 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted self-interview (CASI)
Number of subjects: 616
Study 26241292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - new users of electronic devices
Number of subjects: 2
Study 26241292 — intervention group
Group type: COMPARATOR
Intervention: Electronic Control Group (ECG) - former users of electronic devices
Number of subjects: 2
Study 26241292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 2
Study 26241292 — intervention group
Group type: COMPARATOR
Intervention: Electronic Control Group (ECG)
Number of subjects: 2
Study 23414724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol condition (body-weight-dependent amount of ethanol to achieve a blood alcohol concentration of 1.0‰)
Number of subjects: 14
Study 23414724 — intervention group
Group type: COMPARATOR
Intervention: Sober condition (participants served as their own controls)
Number of subjects: 14
Study 21332286 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study 21332286 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB)
Number of subjects: 0
Study 18947861 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (LPS)
Number of subjects: 159
Study 18947861 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy with lymphadenectomy (LPT)
Number of subjects: 159
Study 17470822 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12)
Number of subjects: 5522
Study 17470822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study 16586193 — intervention group
Group type: EXPERIMENTAL
Intervention: Indianapolis Vocational Intervention Program (IVIP)
Number of subjects: 50
Study 16586193 — intervention group
Group type: COMPARATOR
Intervention: Standard support services
Number of subjects: 50
Study 12472998 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Excel power toothbrush (BPT)
Number of subjects: 67
Study 12472998 — intervention group
Group type: COMPARATOR
Intervention: Sonicare power toothbrush (SPT)
Number of subjects: 67
Study 12472998 — intervention group
Group type: COMPARATOR
Intervention: Philips Sensiflex 2000 power toothbrush (PPT)
Number of subjects: 67
Study 9797188 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg L-NMMA
Number of subjects: 22
Study 9797188 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 22
Study 9797188 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 min)
Number of subjects: 22
Study 8634659 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐carotene (20 mg)
Number of subjects: 227
Study 8634659 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-alpha-tocopheryl acetate (55 mg)
Number of subjects: 227
Study 8634659 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 227
Study 2758537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 or 3.0 microgram.kg‐1)
Number of subjects: 150
Study 2758537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg.kg‐1)
Number of subjects: 150
Study 2758537 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (induction of anaesthesia)
Number of subjects: 150
Study 789268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin
Number of subjects: 28
Study 789268 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cephalothin
Number of subjects: 28
Study 31787409 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare workers who encountered AEFI (n = 120)
Number of subjects: 306
Study 31787409 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of AEFI during the last supervisory visit
Number of subjects: 306
Study 31787409 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to reporting AEFI
Number of subjects: 306
Study 31588974 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning (ETS)
Number of subjects: 132
Study 31588974 — intervention group
Group type: COMPARATOR
Intervention: No endotracheal suctioning (no-ETS)
Number of subjects: 132
Study 28419884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2 g/d)
Number of subjects: 401
Study 28419884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 401
Study 25943360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 88
Study 25943360 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch
Number of subjects: 88
Study 22298434 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance measured with Working Alliance Inventory after session 7
Number of subjects: 100
Study 22298434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment patient variables including personality disorder pathology
Number of subjects: 100
Study 22054415 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 612
Study 22054415 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding on schedule
Number of subjects: 612
Study 17899113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring
Number of subjects: 20
Study 17899113 — intervention group
Group type: COMPARATOR
Intervention: No intrastromal corneal ring (Control)
Number of subjects: 20
Study 17087839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 2 microg kg(‐1)
Number of subjects: 50
Study 17087839 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anaesthesia and caudal block)
Number of subjects: 50
Study 15041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IV
Number of subjects: 240
Study 15041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg IV
Number of subjects: 240
Study 15041600 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 240
Study 15041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.1 mg/mL with morphine in PCA
Number of subjects: 240
Study 15041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg IV
Number of subjects: 240
Study 15041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg IV
Number of subjects: 240
Study 11295924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucocutaneous biopsy specimens analyzed by light microscopy, immunohistochemical analysis, and microbiological analysis (standard viral culture and shell‐vial technique) in studies 1 and 2.
Number of subjects: 56
Study 11295924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucocutaneous biopsy specimens analyzed by light microscopy, immunohistochemical analysis, and microbiological analysis (standard viral culture and shell‐vial technique) in study 3.
Number of subjects: 56
Study 8990448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (estradiol 2.0 mg/d + norethisterone acetate 1.0 mg/d)
Number of subjects: 26
Study 8990448 — intervention group
Group type: COMPARATOR
Intervention: Transdermal HRT (estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d)
Number of subjects: 26
Study 8484508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac, 60 mg
Number of subjects: 60
Study 8484508 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 3437794 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Number of subjects: 12
Study 3437794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 X 10(6) IU/m2 of recombinant interferon (rIFN)‐alpha‐2A, I.M., twice a week for 6 months
Number of subjects: 12
Study 3437794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of rIFN
Number of subjects: 12
Study 3437794 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of rIFN
Number of subjects: 12
Study 3437794 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rIFN‐alpha‐2A therapy
Number of subjects: 12
Study 29471595 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen-III peptide (PIIINP) levels
Number of subjects: 62
Study 29471595 — intervention group
Group type: COMPARATOR
Intervention: T2DM patients with NAFLD
Number of subjects: 62
Study 26842592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 20
Study 26842592 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 20
Study 26842592 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet loading
Number of subjects: 20
Study 25171970 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 685
Study 25171970 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 685
Study 25171970 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography and CT combined
Number of subjects: 685
Study 25171970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction for future prevalence
Number of subjects: 685
Study 23524841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81, 162.5, 325, 650, or 1300 mg daily for 12 weeks)
Number of subjects: 37
Study 19468757 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 19468757 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0
Study 19468757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Risedronate and Estradiol
Number of subjects: 0
Study 19468757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18317236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannose-binding lectin (MBL) deficiency
Number of subjects: 158
Study 18317236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MBL levels
Number of subjects: 158
Study 16899966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group intervention
Number of subjects: 30
Study 14629688 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric students
Number of subjects: 0
Study 14629688 — intervention group
Group type: COMPARATOR
Intervention: Nondysphoric students
Number of subjects: 0
Study 11105328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0
Study 11105328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 0
Study 11105328 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative magnesium
Number of subjects: 0
Study 9392404 — intervention group
Group type: EXPERIMENTAL
Intervention: UNICEF group with restrictive fluid supplements and avoidance of bottles and pacifiers during the first 5 days of life
Number of subjects: 602
Study 9392404 — intervention group
Group type: COMPARATOR
Intervention: Standard group with conventional feeding practice
Number of subjects: 602
Study 9392404 — intervention group
Group type: EXPERIMENTAL
Intervention: UNICEF group
Number of subjects: 602
Study 9392404 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 602
Study 8156252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 100 mg i.v. twice a day for 7 days followed by 400 mg orally three times a day
Number of subjects: 30
Study 8156252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30
Study 8156252 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30
Study 3784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg oral micronised progesterone
Number of subjects: 32
Study 3784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 300 mg oral micronised progesterone
Number of subjects: 32
Study 3784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg or 300 mg oral micronised progesterone
Number of subjects: 32
Study 29241395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) administration
Number of subjects: 0
Study 29241395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27482015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 133
Study 27482015 — intervention group
Group type: COMPARATOR
Intervention: Standard intramedullary cutting jigs
Number of subjects: 133
Study 24881859 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 288
Study 24881859 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 288
Study 22262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (RBCs) transfusion
Number of subjects: 35
Study 22262647 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored red blood cells (RBCs) transfusion (stored for 24.5 days)
Number of subjects: 35
Study 19776372 — intervention group
Group type: EXPERIMENTAL
Intervention: SR1
Number of subjects: 32
Study 19776372 — intervention group
Group type: COMPARATOR
Intervention: SR2
Number of subjects: 32
Study 18766016 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar one-part piano melodies
Number of subjects: 0
Study 18766016 — intervention group
Group type: COMPARATOR
Intervention: Unstructured note sequences
Number of subjects: 0
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha 0.5 mg
Number of subjects: 100
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha 1 mg
Number of subjects: 100
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha 2 mg
Number of subjects: 100
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha 3/4 mg
Number of subjects: 100
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: All TNF-alpha doses
Number of subjects: 100
Study 15930042 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TNF-alpha doses
Number of subjects: 100
Study 12027069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biminne capsules (5 capsules twice a day for 12 weeks)
Number of subjects: 58
Study 12027069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 capsules twice a day for 12 weeks)
Number of subjects: 58